Current management strategies have evolved significantly, with eculizumab—a monoclonal antibody that inhibits the complement component C5—emerging as a prominent therapeutic option that has demonstrated efficacy in halting the progression of renal damage in aHUS patients (14–19). Here, C5 is linked to atypical hemolytic-uremic syndrome.